Pharmaceutical Executive Europe - August 2008 - (Page 13) Pharmaceutical Executive Europe August 2008 Profile 13 Renaissance Man Eric Poincelet is committed to his vision of mobilising European biotech into an industry that can rival the US. Pharm Exec Europe caught up with him to find out how he is engineering the ever-strengthening EuroBio event to help facilitate this. s the exhibition floor of this year’s BIO 2008 International Convention in San Diego was being cleared, and as its 20000-plus attendees were making their way back to their homes and offices across the globe, Eric Poincelet, commissioner general of EuroBio, was immersing himself, some 9000 kilometres away, in the preparations for what he hopes will one day be a true rival to this mammoth US event. Poincelet’s plans for EuroBio are as ambitious and far-reaching as those that propelled US BIO to its current of world domination. There is a long way to go, of course, not least because the European industry has a lot of catching up to do before it can claim any kind of parity with the US. However, Poincelet is quick to point out that European biotech is simply 10 years after the US, and not 10 years behind. EuroBio began life back in 1997 when the French government initiated a European biotechnology networking event known as European Biotech Crossroads. This was, according to Poincelet, a “very French” type of event. Industry was not much involved; rather, it aimed to assist the new generation of researchers “to find a job and discuss the biotech sector.” At this point Poincelet was appointed by Raymond Barre, the former prime minister of France (1976–81) to help launch what became BioVision, the World Life Sciences Forum. Although industry was involved with this, Poincelet was nonetheless frustrated as it was still very much ‘society-oriented.’ “I could see the US Bio event developing at that time,” he says, “and I realised that we needed a meeting for the life sciences industry here in Europe, but nobody was doing it. We had partnering events, financial seminars, conferences here and there, but nothing like the US BIO convention.” When Poincelet left BioVision he was approached by the French Ministry of Research to broaden the scope of the European Biotech Crossroads. He started in 2005 by renaming it EuroBio. “I repositioned it at the interface of industry and research, with industry first; and I basically tried to copy the US event, using everything that I thought worked and discarding what I thought didn’t work.” A Poincelet and his team implemented BIO’s four-pillar structure — the conference, the partnering event, a careers fair and, of course, the exhibition. By 2006, EuroBio was being attended by over 4000 people; this year’s event, in Paris on 7–9 October, is expected to attract over 5000. But for all its ‘internationalisation,’ there is a provocative engagement this year with some of the more controversial issues surrounding biotech in Europe, an approach that smacks, admirably, of a particularly French mentality. “We will be asking questions such as why have we spent so much money, for instance, on the common agricultural policy (CGA) during the past so-many years and why so little on the development of research and innovation,” says Poincelet. “This a strong statement, but it shouldn’t be seen as a provocation. It should be seen as a way of thinking about the future. Every European citizen is spending around €100 per year on growing sugar beet or whatever’s in the framework of the CGA, and only €14 on research and innovation, which is what should be shaping the 21st Century. We’re not saying that we should reduce the money spent on the Common Agricultural Policy — we’re suggesting that maybe there should be a Common Research Policy!” “We’re not saying that we should reduce the money spent on the Common Agricultural Policy — we’re suggesting that maybe there should be a Common Research Policy!” Nationalism and internationalism Despite the growing success of his event, Poincelet is acutely aware of the ongoing disparity between US and European biotech. Indeed, the disparity within Europe — between the UK and the rest of the continent — is a also significant one: the UK industry constitutes 40% of the European biotech industry. It comes as no surprise, then, that the presentations at this year’s EurBio are in English, despite the show being tagged ‘the life sciences event of the European http://www.eurobio2008.com
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Europe - August 2008 Pharmaceutical Executive Europe - August 2008 Contents From the Editor News and Analysis Calendar The Calm Before the Storm Steering Pharma in Russia Built on Sand Renaissance Man IT Meets IMI Send for the Software Specialists Know Your eMarket Last Words Pharmaceutical Executive Europe - August 2008 Pharmaceutical Executive Europe - August 2008 - Pharmaceutical Executive Europe - August 2008 (Page Cover1) Pharmaceutical Executive Europe - August 2008 - Pharmaceutical Executive Europe - August 2008 (Page Cover2) Pharmaceutical Executive Europe - August 2008 - Contents (Page 3) Pharmaceutical Executive Europe - August 2008 - Contents (Page 4) Pharmaceutical Executive Europe - August 2008 - From the Editor (Page 5) Pharmaceutical Executive Europe - August 2008 - News and Analysis (Page 6) Pharmaceutical Executive Europe - August 2008 - News and Analysis (Page 7) Pharmaceutical Executive Europe - August 2008 - Calendar (Page 8) Pharmaceutical Executive Europe - August 2008 - Calendar (Page 9) Pharmaceutical Executive Europe - August 2008 - The Calm Before the Storm (Page 10) Pharmaceutical Executive Europe - August 2008 - Steering Pharma in Russia (Page 11) Pharmaceutical Executive Europe - August 2008 - Built on Sand (Page 12) Pharmaceutical Executive Europe - August 2008 - Renaissance Man (Page 13) Pharmaceutical Executive Europe - August 2008 - Renaissance Man (Page 14) Pharmaceutical Executive Europe - August 2008 - IT Meets IMI (Page 15) Pharmaceutical Executive Europe - August 2008 - IT Meets IMI (Page 16) Pharmaceutical Executive Europe - August 2008 - IT Meets IMI (Page 17) Pharmaceutical Executive Europe - August 2008 - Send for the Software Specialists (Page 18) Pharmaceutical Executive Europe - August 2008 - Send for the Software Specialists (Page 19) Pharmaceutical Executive Europe - August 2008 - Know Your eMarket (Page 20) Pharmaceutical Executive Europe - August 2008 - Know Your eMarket (Page 21) Pharmaceutical Executive Europe - August 2008 - Last Words (Page 22)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.